CBG (cannabigerol) is by far one of the most important cannabinoids in the cannabis plant. It is often called “the mother of all cannabinoids,” and it holds potential as a treatment for conditions such as diabetes, ALS, and Huntington’s disease, although human studies are seriously lacking. In addition to its potential medical applications, much like CBD, CBG is not considered intoxicating and will not get you high.
Many of the more popular and well-known effects of THC and CBD are derived from their interaction with the endocannabinoid system. CBG, however, mainly works through other mechanisms, which explains why it has such different effects. It is currently being researched as a treatment for a long list of conditions, such as dementia, PTSD, ADHD, Huntington’s disease, ALS, Parkinson’s disease, multiple sclerosis, diabetes, colitis, and of course, pain.
First isolated by Rephael Mechulam and Yehiel Gaoni in 1964, CBG is often referred to as “the mother of all cannabinoids,” suggesting that it is superior to other cannabinoids. What the “mother of all cannabinoids” really means is that CBGA is produced first by the plant, then is converted to other cannabinoid acids. So really, CBGA is responsible for the creation of THCA, CBDA, and CBCA because the plant needs CBGA to make them. This is important for scientists researching the plant.
In fact, CBG usually occurs in much lower concentrations than other cannabinoids like THC and CBD — typically around 0-1% in a cannabis flower. With the hype surrounding CBG in the past few years, however, breeders have been developing CBG-dominant varieties, and companies are producing a multitude of products such as CBG oils and flowers.
The benefits of CBG
CBG presents a rich pharmacological profile that could potentially have a lot of benefits for neurodegenerative conditions like Huntigton’s disease, ALS, Parkinson’s disease, and MS. It may also be of great benefit in inflammatory conditions like colitis, and also for metabolic conditions like diabetes and obesity. CBD Clinic Care is proud to offer CBG in Isolate & Distillate form for your formulation needs.
Lately we’ve been hearing more and more about cannabinoids, especially THC and CBD. But you’ve probably never heard of cannabichromene, also known as CBC. Discovered over 50 years ago, CBC is considered one of the six outstanding cannabinoids in medical research. It doesn’t get the same attention as other cannabinoids, but the benefits of the cannabinoid CBC are extremely promising.
CBC has the same origins as THC and CBD, all of which are derived from cannabigerolic acid (CBGA). Cannabis plants produce CBGA, the precursor to three main cannabinoids: tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromene carboxylic acid (CBCA).
For CBC, it converts from CBGA to cannabichromene carboxylic acid (CBCA), and then finally to CBC after exposure to heat or ultraviolet light.
What is CBC?
Cannabichromene belongs to the family of organic compounds known as cannabinoids. Contained in hemp and different varieties of marijuana, CBC is synthesized after CBCA is exposed to heat and light. However, it is different from most cannabinoids because it has a low affinity for our CB receptors. Instead, CBC binds to TRPV receptors involved in the perceptions of temperature changes and other stimuli at the cellular level. Although CBC can bring benefits individually, most studies have examined the effects of CBC along with other cannabinoids such as CBD and THC. Cannabichromene shows excellent synergy with other cannabinoids, but despite being an important compound within the biological structure of Cannabis sativa, it is only produced in small amounts.
CBC does not cause intoxication, it does not produce euphoria, like THC. The reason it is not intoxicating is that it binds poorly to CB1 cannabinoid receptors in the brain. But CBC does bind to other receptors in the body, such as vanilloid receptor 1 (TRPV1) and transient potential ankyrin receptor 1 (TRPA1), both of which are linked to pain perception. When CBC activates these receptors, elevated levels of the body’s natural endocannabinoids, such as anandamide, are released.
CBC has separate benefits, but researchers also believe it works in synergy with other cannabinoids, a term known as the entourage effect. This effect of THC working together with CBD is well known, but it is not known whether other cannabinoids also have an entourage effect.
Cannabichromene has been shown to block the pain and inflammation associated with osteoarthritis. Cannabinoids such as CBC act on inflammation differently than nonsteroidal anti-inflammatory drugs (NSAIDs) and do not have the side effects of these drugs. In another example of an entourage effect, CBC in combination with THC had a significant anti-inflammatory response in an animal study: together, the two cannabinoids produced a much greater effect on inflammation than separately.
The benefits that CBC would have have far-reaching implications. Below are some medical conditions that can be alleviated by cannabichromene.
Cannabichromene may be a powerful cancer fighter, and the reason might be its interaction with the body’s natural endocannabinoid, anandamide. CBC also appears to inhibit the uptake of anandamide, allowing it to remain longer in the bloodstream.
A recent study in which tumor growth was initiated in mice (two-stage mouse skin carcinogenesis model) showed cannabinoids might be effective in inhibiting both inflammation and tumor growth. Since anandamide has been shown to fight breast cancer in vitro and in vivo, this shows promise that CBC and other cannabinoids might one day be a chemopreventive agent.
CBC as a potential cancer fighter was first published in a 2006 study that looked at cannabinoids other than THC and their possible effects on cancer. While THC is known for its anti-tumor properties for several different forms of cancer, its powerful psychotropic qualities can make it difficult for chemotherapy use. So far, research has found CBC to be the second-most-potent cannabinoid at inhibiting the growth of new cancer cells (CBG was the most potent).
Pain and Inflammation
Cannabichromene has been shown to block pain and inflammation associated with collagen-induced osteoarthritis. Cannabinoids like CBC act on inflammation differently than non-steroidal anti-inflammatory drugs (NSAIDs) do, and don’t have the side effects of these medications. In another example of the entourage effect, CBC in combination with THC had significant anti-inflammatory response in a recent animal study; together, the two cannabinoids produced a much greater effect on inflammation than by themselves.
In a 2013 mouse study, CBC had a positive effect on neural stem progenitor cells (NSPCs), a cell essential to healthy brain function. NSPCs became more viable when in the presence of CBC, and that shows promise because NSPCs differentiate into astroglial cells, the most important cells for maintaining brain homeostasis. The astroglial cells perform a whole host of functions, including neurotransmitter direction and defending against oxidative stress. Astroglia counteract many of these issues—oxidative stress, inflammation, toxicity—that create neurological diseases and brain pathologies like Alzheimer’s disease.
A research team that had previously shown CBD’s effect on acne studied other cannabinoids, including CBC, for the same effects. Indeed, CBC was shown to be a powerful inhibitor of acne. As a skin disease, acne is characterized by excess sebum production and sebaceous gland inflammation. It turns out that CBC exhibited powerful anti-inflammatory properties and also suppressed excessive lipid production in the sebaceous glands. CBC also reduced levels of arachidonic acid (AA), which is needed to create the lipogenesis. More research is needed, but CBC might just one day become a very powerful antiacne treatment.